Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ICI 182, 780 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ICI 182,780 (Faslodex) | DRUG | - |
Inclusion Criteria: * Premenopausal women with SLE * Without life-threatening manifestations * With regular menstrual cyles not on hormones of any kind Exclusion Criteria: For any of the following: * Increase of SLEDAI greater than 12 * If life-threatening manifestations occur * If menstruation ...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
ICI 182,780 is being studied for the treatment of Systemic Lupus Erythematosus (SLE). It is an investigational small molecule in Phase 2 clinical development. The drug is being evaluated in a completed clinical trial that enrolled 20 female participants aged 16 years and older in the United States.
ICI 182,780 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 2 clinical development for Systemic Lupus Erythematosus.
ICI 182,780 is in Phase 2 clinical development. It is an investigational drug being studied for Systemic Lupus Erythematosus. The drug has completed one Phase 2 clinical trial, and it is not yet approved for any use.
ICI 182,780 has been studied in a completed Phase 2 clinical trial registered as NCT00417430. The trial, titled 'Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies,' enrolled 20 participants with Systemic Lupus Erythematosus in the United States.
ICI 182,780 is also known as Faslodex. The completed clinical trial NCT00417430 for Systemic Lupus Erythematosus refers to the drug as Faslodex. This alternative name is used in the context of the clinical study.